MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.090
+0.070
+1.74%
After Hours: 4.120 +0.03 +0.73% 17:04 01/24 EST
OPEN
4.000
PREV CLOSE
4.020
HIGH
4.120
LOW
3.750
VOLUME
1.92M
TURNOVER
--
52 WEEK HIGH
11.74
52 WEEK LOW
3.750
MARKET CAP
489.70M
P/E (TTM)
-7.8699
1D
5D
1M
3M
1Y
5Y
BRIEF-Affimed Announces Completion of Enrollment in the Registration-Directed Study of AFM13 in PTCL
reuters.com · 01/06 11:38
Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose level, and (ii) treatment of patients with more than two...
GlobeNewswire · 01/06 11:30
Timothy P. Lynch’s Stonepine Capital Portfolio: Top 10 Healthcare Stocks
In this article, we discuss the top 10 healthcare stock picks of Timothy P. Lynch’s Stonepine Capital. If you want to skip our detailed analysis of these stocks, go directly to Timothy P. Lynch’s Stonepine Capital Portfolio: Top 5 Healthcare Stocks. Timoth...
Insider Monkey · 12/11/2021 16:59
Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq
Zacks.com · 12/09/2021 15:38
Affimed, Roche commences patient recruitment in Phase 1/2a trial of AFM24 + atezolizumab
Affimed (NASDAQ:AFMD) has initiated patient recruitment for Phase 1/2a study evaluating the safety, tolerability, pharmacokinetics and efficacy of the innate cell engager (ICE) AFM24 in combination with Roche’s (OTCQX:RHHBY) atezolizumab.
Seekingalpha · 12/08/2021 13:14
BRIEF-Affimed Initiates Patient Recruitment for Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab
reuters.com · 12/08/2021 11:35
Could The Affimed N.V. (NASDAQ:AFMD) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Affimed N.V. ( NASDAQ:AFMD ) can tell us which group is most powerful. Generally...
Simply Wall St. · 12/05/2021 11:04
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
Affimed NV (NASDAQ: AFMD) has announced 
Benzinga · 11/22/2021 14:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AFMD. Analyze the recent business situations of Affimed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

42.86%Strong Buy
57.14%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AFMD stock price target is 13.23 with a high estimate of 17.81 and a low estimate of 10.88.
High17.81
Average13.23
Low10.88
Current 4.090
EPS
Actual
Estimate
-0.17-0.12-0.08-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 150
Institutional Holdings: 77.17M
% Owned: 64.45%
Shares Outstanding: 119.73M
TypeInstitutionsShares
Increased
44
4.85M
New
15
5.66M
Decreased
39
3.64M
Sold Out
35
7.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Chairman - Supervisory/Independent Director
Thomas Hecht
Chief Executive Officer/Management Board
Adi Hoess
Chief Financial Officer/Management Board
Angus Smith
Chief Operating Officer/Management Board
Wolfgang Fischer
Chief Scientific Officer/Management Board
Arndt Schottelius
Management Board
Andreas Harstrick
Management Board
Denise Mueller
Independent Director/Supervisory Board
Bernhard Ehmer
Independent Director/Supervisory Board
Ulrich Grau
Independent Director/Supervisory Board
Mathieu Simon
Independent Director/Supervisory Board
Ferdinand Verdonck
Supervisory Board
Annalisa Jenkins
Supervisory Board
Uta Kemmerich-Keil
Supervisory Board
Harry Welten
No Data
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.